- The trend backdrop is active with a 7-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
KRONOX
NSI
Week ended 07 Aug 2026
Weekly Investor Report
KRONOX LAB SCIENCES LTD · Basic Materials · Specialty Chemicals
Latest close
163.6 INR
8.1%
latest week
Weekly setup
Constructive, but selective
The weekly trend is active. Price is 22.5% above the Trend Line and sits at 79.9% of its 52-week range. The latest completed week returned 8.1%, after a 8.5% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 48/100.
Setup score
67
out of 100
Latest Close
163.6 INR
7 Aug 2026
1W Return
8.1%
latest completed week
4W Return
8.5%
short-term follow-through
12W Return
24.3%
quarterly tape
Trend Breadth
28.8%
15 of 52 weeks active
Volume Ratio
2.4x
vs 13-week average
- Next-week expectancy is negative at 36.32% based on similar historical setup states.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
8.1%
Latest completed week; four-week move 8.5%.
Indicator stack
40/70
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 36.32%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
48/100
25 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 22.5% above the Trend Line and sits at 79.9% of its 52-week range. The latest completed week returned 8.1%, after a 8.5% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 2.4x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.6412-week average 0.40
12-week confirmation
Trend active7/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership9/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.64Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 8.5% over four weeks, 24.3% over 12 weeks, and -0.8% over one year. The current trend has remained active for 7 consecutive weeks.
Performance by holding period
Active trend streak7 weeks
Active weeks in one year15
Trend breadth28.8%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure1.13Latest activity-pressure read.
Pressure change-4.3%Four-week change in activity pressure.
Leadership16.49Latest relative-leadership reading.
RS change110.0%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 91%
Model confidence 85%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength59/100Blend of value, momentum, and quality. Underlying universe rank 42; rank 1 is best.
Value42/100Relative valuation strength. Underlying universe rank 59; rank 1 is best.
Quality93/100Profitability and accounting quality. Underlying universe rank 8; rank 1 is best.
Momentum37/100Medium-term price momentum. Underlying universe rank 64; rank 1 is best.
Growth22/100Revenue and earnings growth. Underlying universe rank 79; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework72/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 22.0x Price divided by trailing earnings.
- Price / sales
- 6.0x Market value relative to trailing revenue.
- EV / EBITDA
- 15.4x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 3.4% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 53.9% Gross profit retained from each unit of revenue.
- Operating margin
- 31.7% Operating profit retained from revenue.
- Free-cash-flow margin
- 20.3% Free cash flow generated from revenue.
- Return on invested capital
- 20.9% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 1.0% Latest one-year revenue growth.
- EPS growth
- 8.6% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- -25.4% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 5/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 0.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- -0.0x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment48/100
Weighted news tone is neutral across 25 relevant articles.
1 positive · 21 neutral · 3 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-9.4%Distance below the 52-week high.
13-week volatility5.1%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher13 of 2613 weeks finished lower.
Best week+16.7%Week of 3 Apr.
Worst week-7.9%Week of 27 Mar.
Latest week+8.1%Week of 7 Aug.
Shape of recent returns
Strong gains6
Modest gains7
Flat weeks0
Modest losses7
Sharp losses6
Recent vol5.1%13-week weekly-return volatility.
Base vol5.1%52-week weekly-return volatility.
Up/down split21/31Count of positive and negative weeks in the 52-week window.
Average skew4.6% / -2.9%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorIN Basic Materials
4-week rank- / 100
Group average2.8%
Trend breadth52.0%
Trend52.0%active weekly trend signals
MD52.0%positive activity pressure
RS63.0%positive relative leadership
Four-week leaders
IndustryIN Specialty Chemicals
4-week rank33 / 100
Group average5.8%
Trend breadth77.0%
Trend77.0%active weekly trend signals
MD75.0%positive activity pressure
RS72.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape61/100
Trend, activity pressure, participation, and risk combine to a 61/100 tape read.
Indicator analysis70/100Latest 12-week confirmation: trend 7/12, activity pressure 12/12, relative leadership 9/12.
Activity pressure 0.64; No reversal markers Next-Week ExpectancyNegative 36.32%Next-week expectancy is negative with a 36.32% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors58/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 41; Small Cap Core rank 70 SVQF72/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 438.5 of 1576 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment48/100Weighted news tone is neutral across 25 relevant articles.
KRONOX Lab Sciences Limited Issues Clarification on Share Price Movement Under Regulation 30 Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 163.6 INR | 8.1% | 133.5 INR | 155.2 INR | 1.13 | 16.49 | 1.1M | On |
| 31 Jul 2026 | 151.3 INR | -2.0% | 132.5 INR | 155.1 INR | 1.18 | 8.55 | 339.6K | On |
| 24 Jul 2026 | 154.4 INR | 1.6% | 132.2 INR | 155.1 INR | 1.23 | 13.28 | 577.5K | On |
| 17 Jul 2026 | 151.9 INR | 0.8% | 131.7 INR | 155.1 INR | 1.22 | 8.60 | 2.6M | On |
| 10 Jul 2026 | 150.8 INR | -4.6% | 131.4 INR | 155.1 INR | 1.18 | 7.85 | 479.1K | On |
| 3 Jul 2026 | 158.0 INR | 3.2% | 131.1 INR | 155.2 INR | 0.96 | 12.20 | 104.7K | On |
| 26 Jun 2026 | 153.1 INR | 0.2% | 130.5 INR | 155.2 INR | 0.80 | 9.28 | 0 | On |
| 19 Jun 2026 | 152.8 INR | 13.5% | 130.1 INR | 155.2 INR | 0.80 | 8.90 | 121.0K | Off |
| 12 Jun 2026 | 134.6 INR | 1.1% | 129.8 INR | 155.2 INR | 0.74 | -2.55 | 28.2K | Off |
| 5 Jun 2026 | 133.1 INR | -4.1% | 130.3 INR | 155.4 INR | 0.80 | -2.93 | 30.4K | Off |
| 29 May 2026 | 138.9 INR | 1.5% | 130.7 INR | 155.6 INR | 0.92 | 0.15 | 340.2K | Off |
| 22 May 2026 | 136.9 INR | 4.1% | 131.0 INR | 155.8 INR | 0.97 | -2.33 | 176.7K | Off |
| 15 May 2026 | 131.6 INR | -6.5% | 131.5 INR | 156.0 INR | 0.94 | -5.83 | 231.8K | Off |
| 8 May 2026 | 140.7 INR | 0.1% | 132.1 INR | 156.2 INR | 0.97 | -1.53 | 195.4K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.